BioWorld MedTech

Nov. 29, 2016

TAVR pioneer Edwards enters TMVR market with Valtech Cardio acquisition

Edwards Lifesciences Corp. has agreed to acquire Or Yehuda, Israel-based Valtech Cardio Ltd. for $340 million, with the potential for $350 million in additional milestone payments. Read More

Revised Cures bill, minus mandatory NIH funding, heads for 2nd House vote

GE and Boston Children's collaboration targets childhood brain diseases

FDA adds details to performance tests in endoscope safety final

Single patent system to be ratified by U.K.

Daily M&A

Financings

Other news to note

Regulatory front

Product briefs

MDD's Cardiology Extra

Today's news in brief

BioWorld

BioWorld briefs for April 4, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 4, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

3D rendering of glucagon-like peptide 1 (GLP-1)

ADPD 2025: Unlocking GLP-1's potential in neurodegeneration

BioWorld

At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk A/S, who has extensive experience in...

Immune checkpoint inhibitors illustration of PD-1, CTLA-4 and PD-L1.

Checkpoint inhibitor journey traces Chinese firms’ path to global revenue

BioWorld

Chinese pharmaceutical companies are making significant inroads into the global oncology market, particularly with the development and approval of immune...